Genentech signs $534M deal with Microbiotica to search gut bacteria for IBD targets, new drugs

Genentech has signed a multiyear contract to pan the diverse bacteria living in the digestive tract for biomarker signatures of drug response, new live bacterial therapeutics and novel targets for inflammatory bowel disease.